BioStock: CombiGene comments on the discontinued CGT2 project

CombiGene has terminated the preclinical development of the lipodystrophy project CGT2 after the data did not prove to be convincing enough to justify its continuation. According to the company, the discontinuation of the project means that resources can now be freed up for the COZY pain project in particular.

Read the full interview with Peter Ekolind at biostock.se:

https://www.biostock.se/en/2024/02/combigene-comments-on-the-discontinued-cgt2-project/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/